In clinical studies, burping was reported as a side effect with most GLP-1 drugs: Ozempic (semaglutide) injecton: 3% of patients taking the 0.5 mg dose, and 1% of patients taking the 1 mg dose
In it, adults taking the once-daily 25mg tablet lost an average of 16.6% of their starting body weight over 64 weeks, compared with 2.7% for those on placebo
Comparison Table (Structure, Pathway, Research Classification) Each compounds classification reflects its underlying mechanism rather than a shared fat-loss peptide category: AOD-9604 remains research-stage and inconclusive, GLP-1 S has the most extensive clinical backing of the three, and tesamorelin occupies a narrower but well-documented niche in visceral fat and GH-axis research
Customer ratings and testimonials are brand-reported, not independently verified
Where much of the market treats 98% as acceptable, Protide publishes batch-specific data that exceeds it